https://sciex.com/content/SCIEX/na/us/en


On Demand Videos from the 2017 Global CESI-MS Symposium

Dec 1, 2017 | Biopharma, Blogs, Life Science Research | 0 comments

Bringing Together KOLs and Scientists from Around the World

The 2017 Global CESI-MS Symposium brought together KOLs and industry innovators from around the world to share their latest advancements using capillary electrophoresis integrated with electrospray ionization (CESI-MS) within the same device.

Hosted by Dr. Alexander Ivanov at the renowned Barnett Institute on the campus of Northeastern University, the 2017 Global CESI-MS Symposium was held in Boston, Massachusetts, on October 5-6, 2017.

Attendees at the conference heard how industry innovators have revealed hidden information not seen before such as proteoforms and peptides; intact mAb charge variants; native proteins; isobaric metabolites and glycans not resolved by traditional techniques; and charged and polar analytes.

The Symposium was hosted by Professor Alexander R. Ivanov, at the Barnett Institute, on the campus of Northeastern University, with sessions chaired by:

Proteomics and Metabolomics:

  • Professor Alexander Ivanov, Northeastern University
  • Professor Jennifer Van Eyk, Cedars Sinai Medical Center, USA

Novel and Advanced Applications

  • Dr. Spencer Walse, USDA-ARS, USA

Biopharma

  • Professor John R. Yates III, The Scripps Research Institute, USA

In case you were not able to attend or experience the live presentations online, we have made them available on-demand >

Join us next year in The Netherlands! Stay tuned for more information.

Questions and answers to help improve your mycotoxin analysis

During a recent webinar I shared method details for mycotoxin analysis on the SCIEX 7500 system. In this blog i will share the Q&A for the submitted questions that we did not have chance to answer during the live webinar.

A 2-fold revolution: MS approaches for the bioanalysis of oligonucleotide therapeutics

In 1998, the US Food and Drug Administration (FDA) approved fomivirsen as the first therapeutic oligonucleotide therapeutic. This approval marked a revolution of mechanism of action discovered decades before finally coming to fruition. Since then, the landscape of chemical modifications of oligonucleotides, conjugations and formulations has evolved tremendously, contributing to improvements in stability, efficacy and safety. Today, more than a dozen antisense oligonucleotides (ASOs) and small interfering RNA (siRNA) drugs are on the market, most of which are designated as orphan drugs for treating rare genetic diseases.

Is “right first time, every time” a pipedream for metabolite identification by LC-MS?

If we lived in an ideal world, it would be possible to unambiguously identify metabolites using a single analytical experiment. This analytical technique would need to be efficient and easily generate the information needed from a routine assay that is also robust, enabling confident decision-making during drug discovery.

Posted by

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial